Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does palliative chemotherapy beyond three courses benefit patients with non-small-cell lung cancer?

Nature Clinical Practice Oncology volume 4, pages 274–275 (2007)Cite this article

boxed-textvon Plessen C et al. (2006) Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 95: 966–973

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Smith IE et al. (2001) Duration of chemotherapy in advanced non small cell lung cancer: a randomised trial of three versus six courses of mitomycin C, vinblastine, and cisplatin. J Clin Oncol 19: 1336–1343

    Article  CAS  Google Scholar 

  2. Socinski MA et al. (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20: 1335–1343

    CAS  PubMed  Google Scholar 

  3. Weestel V et al. (2005) Randomised study of maintenance vinorelbine in responders with advanced non small cell lung cancer. J Natl Cancer Inst 97: 499–506

    Article  Google Scholar 

  4. Brodowicz T et al. (2006) Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non small cell lung cancer: a phase III trial. Lung Cancer 52: 155–163

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Division of Medical Oncology, 'SG Moscati' Hospital, Contrada Amoretta, 83100 Avellino, Italy cgridelli@libero.it

Authors and Affiliations

  1. C Gridelli is Chief of the Division of Medical Oncology and Director of the Department of Oncology/Hematology at the 'SG Moscati' Hospital of Avellino, Avellino, Italy.,

    Cesare Gridelli

Authors
  1. Cesare Gridelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gridelli, C. Does palliative chemotherapy beyond three courses benefit patients with non-small-cell lung cancer?. Nat Rev Clin Oncol 4, 274–275 (2007). https://doi.org/10.1038/ncponc0776

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0776

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing